mexiletine has been researched along with Erythermalgia in 12 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1." | 5.40 | Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. ( Bennett, DL; Cox, JJ; Cregg, R; Werdehausen, R; Wood, JN, 2014) |
| "Treatment with mexiletine reduced the number and severity of pain episodes." | 5.35 | Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. ( Choi, JS; Dib-Hajj, SD; Han, C; Lin, Z; Tyrrell, L; Wang, X; Waxman, SG; Yang, Y; Zhang, L, 2009) |
| "Erythromelalgia is a rare, chronic, debilitating condition characterized by redness, warmth, and severe burning pain of the distal extremities." | 5.33 | Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. ( Guite, JW; Hehir, D; Milovcich, K; Nathan, A; Rose, JB, 2005) |
| "In a family exhibiting severe familial erythermalgia involving 5 members over 3 generations, we treated 4 patients aged 41, 39, 19 and 15 years." | 5.32 | [Treatment of familial erythermalgia with the association of lidocaine and mexiletine]. ( Dupre, D; Guillet, G; Kupfer, I; Legroux-Crespel, E; Misery, L; Sassolas, B, 2003) |
| "Erythromelalgia is a condition characterized by episodic pain, erythema and temperature of the extremities, which is relieved by cooling and aggravated by warming." | 2.61 | Review of primary and secondary erythromelalgia. ( King, T; Mann, N; Murphy, R, 2019) |
| "Once erythromelalgia was suspected clinically, the SCN9A gene was sequenced." | 2.50 | An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder. ( Meijer, IA; Nizard, S; Robitaille, Y; Rossignol, E; Vanasse, M, 2014) |
| "The treatment of primitive erythermalgia is based on sodium channel blockers such as mexiletine or lidocaine infusions, and on drugs effective on neuropathic pain, such as gabapentin or amitryptiline, in case of erythermalgia associated with small fiber neuropathy." | 1.72 | [Paroxysmal vascular acrosyndromes: Practical approach to diagnosis and management]. ( Senet, P, 2022) |
| "Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1." | 1.40 | Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. ( Bennett, DL; Cox, JJ; Cregg, R; Werdehausen, R; Wood, JN, 2014) |
| "Erythromelalgia is a rare disorder characterized by recurrent pain attacks, swelling and redness in the distal extremities." | 1.38 | Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations. ( Berner, R; Creutzfeldt, R; Hufnagel, M; Jakob, A; Staszewski, O; Winterpacht, A, 2012) |
| "Treatment with mexiletine reduced the number and severity of pain episodes." | 1.35 | Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. ( Choi, JS; Dib-Hajj, SD; Han, C; Lin, Z; Tyrrell, L; Wang, X; Waxman, SG; Yang, Y; Zhang, L, 2009) |
| "Erythromelalgia is a rare, chronic, debilitating condition characterized by redness, warmth, and severe burning pain of the distal extremities." | 1.33 | Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. ( Guite, JW; Hehir, D; Milovcich, K; Nathan, A; Rose, JB, 2005) |
| "In a family exhibiting severe familial erythermalgia involving 5 members over 3 generations, we treated 4 patients aged 41, 39, 19 and 15 years." | 1.32 | [Treatment of familial erythermalgia with the association of lidocaine and mexiletine]. ( Dupre, D; Guillet, G; Kupfer, I; Legroux-Crespel, E; Misery, L; Sassolas, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Senet, P | 1 |
| Mann, N | 1 |
| King, T | 1 |
| Murphy, R | 1 |
| Meijer, IA | 1 |
| Vanasse, M | 1 |
| Nizard, S | 1 |
| Robitaille, Y | 1 |
| Rossignol, E | 1 |
| Cregg, R | 1 |
| Cox, JJ | 1 |
| Bennett, DL | 1 |
| Wood, JN | 1 |
| Werdehausen, R | 1 |
| Patel, N | 1 |
| Chen, E | 1 |
| Cucchiaro, G | 1 |
| Choi, JS | 1 |
| Zhang, L | 1 |
| Dib-Hajj, SD | 1 |
| Han, C | 1 |
| Tyrrell, L | 1 |
| Lin, Z | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Waxman, SG | 1 |
| Jakob, A | 1 |
| Creutzfeldt, R | 1 |
| Staszewski, O | 1 |
| Winterpacht, A | 1 |
| Berner, R | 1 |
| Hufnagel, M | 1 |
| Elgueta, F | 1 |
| de la Cuadra-Fontaine, JC | 1 |
| Clede, L | 1 |
| Fierro, C | 1 |
| Valderrama, A | 1 |
| Legroux-Crespel, E | 1 |
| Sassolas, B | 1 |
| Guillet, G | 1 |
| Kupfer, I | 1 |
| Dupre, D | 1 |
| Misery, L | 1 |
| Jang, HS | 1 |
| Jung, D | 1 |
| Kim, S | 1 |
| Jo, J | 1 |
| Lee, J | 1 |
| Kim, M | 1 |
| Oh, C | 1 |
| Kwon, K | 1 |
| Nathan, A | 1 |
| Rose, JB | 1 |
| Guite, JW | 1 |
| Hehir, D | 1 |
| Milovcich, K | 1 |
| Kuhnert, SM | 1 |
| Phillips, WJ | 1 |
| Davis, MD | 1 |
2 reviews available for mexiletine and Erythermalgia
| Article | Year |
|---|---|
Review of primary and secondary erythromelalgia.
Topics: Capsaicin; Erythromelalgia; Humans; Mass Screening; Mexiletine; Myeloproliferative Disorders; NAV1.7 | 2019 |
An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
Topics: Carbamazepine; Child, Preschool; Comorbidity; Erythromelalgia; Female; Humans; Hypesthesia; Mexileti | 2014 |
10 other studies available for mexiletine and Erythermalgia
| Article | Year |
|---|---|
[Paroxysmal vascular acrosyndromes: Practical approach to diagnosis and management].
Topics: Antibodies, Antinuclear; Aspirin; Calcium Channel Blockers; Erythromelalgia; Gabapentin; Humans; Ilo | 2022 |
Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.
Topics: Analgesics; Erythromelalgia; HEK293 Cells; Humans; Ion Channel Gating; Mexiletine; Mutagenesis, Site | 2014 |
The Complexity of Pain Management in Patients with Erythromelalgia.
Topics: Adolescent; Combined Modality Therapy; Electric Stimulation Therapy; Erythromelalgia; Female; Humans | 2015 |
Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.
Topics: Anti-Arrhythmia Agents; Biophysics; Cell Line, Transformed; Child; Chromosomes, Human, Pair 15; Dose | 2009 |
Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.
Topics: Administration, Oral; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Diagnosis, Differentia | 2012 |
Erythromelagia: a rare and hard-to-treat condition: a 9-year-old boy responsive to intravenous lidocaine and oral mexilitene.
Topics: Administration, Intravenous; Administration, Oral; Child; Erythromelalgia; Humans; Lidocaine; Male; | 2013 |
[Treatment of familial erythermalgia with the association of lidocaine and mexiletine].
Topics: Administration, Oral; Adolescent; Adult; Anesthetics, Local; Dose-Response Relationship, Drug; Drug | 2003 |
A case of primary erythromelalgia improved by mexiletine.
Topics: Adult; Dermatologic Agents; Erythromelalgia; Humans; Leg Dermatoses; Male; Mexiletine | 2004 |
Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment.
Topics: Administration, Oral; Analgesia, Epidural; Anesthetics, Local; Bupivacaine; Child; Erythromelalgia; | 2005 |
Lidocaine and mexiletine therapy for erythromelalgia.
Topics: Administration, Oral; Adult; Drug Therapy, Combination; Erythromelalgia; Follow-Up Studies; Humans; | 1999 |